Publication Date

12-1-2024

Journal

Cancer Research Communications

DOI

10.1158/2767-9764.CRC-24-0281

PMID

39601621

PMCID

PMC11683667

PubMedCentral® Posted Date

12-30-2024

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Keywords

Humans, Glioma, Animals, Mice, Membrane Glycoproteins, CD83 Antigen, Antigens, CD, Immunoglobulins, Brain Neoplasms, Disease Progression, Cell Line, Tumor, Immune Tolerance, CD8-Positive T-Lymphocytes, Cytokines, Immunosuppression Therapy

Abstract

Immunosuppression in malignant glioma remains a barrier to therapeutic development. CD83 overexpression in human and mouse glioma increases survival. CD83+ tumor cells promote signatures related to cytotoxic T cells, enhanced activation of CD8+ T cells, and increased proinflammatory cytokines. These findings suggest that tumor-expressed CD83 could mediate tumor-immune communications.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.